Table of contents

Clinical and epidemiological research

• Extended report: Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study (30 September, 2014) Free

  Thomas Frauenfelder, Anna Winklehner, Thi Dan Linh Nguyen, Rucsandra Dobrota, Stephan Baumueller, Britta Maurer, Oliver Distler
• Extended report: Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial (29 July, 2013)

  Raphaèle Seror, Gabriel Baron, Eric Hachulla, Michel Debandt, Claire Larroche, Xavier Puéchal, François Maurier, Benoît de Wazieres, Thomas Quéméneur, Philippe Ravaud, Xavier Mariette
• The effect of FTO variation on increased osteoarthritis risk is mediated through body mass index: a mendelian randomisation study

  (6 August, 2013)

  Kalliope Panoutsopoulou, Sarah Metrustry, Sally A Doherty, Laura L Laslett, Rose A Maciewicz, Deborah J Hart, Weiya Zhang, Kenneth R Muir, Margaret Wheeler, Cyrus Cooper, Tim D Spector, Flavia M Cicuttini, Graeme Jones, Nigel K Arden, Michael Doherty, Eleftheria Zeggini, Ana M Valdes, arcOGEN Consortium
• Extended report: Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis (12 August, 2013)

  Tünde Minier, Serena Guiducci, Silvia Bellando-Randone, Cosimo Bruni, Gemma Lepri, László Czirják, Oliver Distler, Ulrich A Walker, Jaap Fransen, Yannick Allanore, Christopher Denton, Maurizio Cutolo, Alan Tyndall, Ulf Müller-Ladner, Marco Matucci-Cerinic, and the EUSTAR co-workers
• Extended report: Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension (5 August, 2013)

  Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Bernard Combe, Vibeke Strand, Philip Mease, Laura Shaughnessy, Brenda VanLunen, Désirée van der Heijde
• Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout

  (11 September, 2013)

  Caitlin Batt, Amanda J Phipps-Green, Michael A Black, Murray Cadzow, Marilyn E Merriman, Ruth Topless, Peter Gow, Andrew Harrison, John Highton, Peter Jones, Lisa Stamp, Nicola Dalbeth, Tony R Merriman
• Extended report: Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national medicare data (18 September, 2013)

  Jasvinder A Singh, Xin Lu, Gary E Rosenthal, Said Ibrahim, Peter Cram
• Extended report: Prediction model for knee osteoarthritis incidence, including clinical, genetic and biochemical risk factors (20 August, 2013)

  H J M Kerkhof, S M A Bierma-Zeinstra, N K Arden, S Metrustry, M Castano-Betancourt, D J Hart, A Hofman, F Rivadeneira, E H G Oei, Tim D Spector, A G Uitterlinden, A C J W Janssens, A M Valdes, J B J van Meurs
• Extended report: Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries (6 August, 2013)

  Mwidimi Ndosi, Ann Bremander, Bente Hamnes, Mike Horton, Marja Leena Kukkurainen, Pedro Machado, Andrea Marques, Jorit Meesters, Tanja A Stamm, Alan Tennant, Jenny de la Torre-Aboki, Theodora P M Vliet Vlieland, Heidi A Zangi, Jackie Hill
• Extended report: A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip (29 August, 2013)

  Evangelos Evangelou, Hanneke J Kerkhof, Unnur Styrkarsdottir, Evangelia E Ntzani, Steffan D Bos, Tonu Esko, Daniel S Evans, Sarah Metrustry, Kalliope Panoutsopoulou, Yolande F M Ramos, Gudmar Thorleifsson, Konstantinos K Tsilidis, arcOGEN Consortium, Nigel Arden, Nadim Aslam, Nicholas Bellamy, Fraser Birrell, Francisco J Blanco, Andrew Carr, Kay Chapman, Aaron G Day-Williams, Panos Deloukas, Michael Doherty, Gunnar Engström, Hafdis T Helgadottir, Albert Hofman, Thorvaldur Ingvarsson, Helgi Jonsson, Aime Keis, J Christiaan Keurentjes, Margreet Kloppenburg, Penelope A Lind, Andrew McCaskie, Nicholas G Martin, Lili Milani, Grant W Montgomery, Rob G H H Nelissen, Michael C Nevitt, Peter M Nilsson, William ER Ollier, Neeta Parimi, Ashok Rai, Stuart H Ralston, Mike R Reed, Jose A Riancho, Fernando Rivadeneira, Cristina Rodriguez-Fontenla, Lorraine Southam, Unnur Thorsteinsdottir, Aspasia Tsezou, Gillian A Wallis, J Mark Wilkinson, Antonio Gonzalez, Nancy E Lane, L Stefan Lohmander, John Loughlin, Andres Metspalu, Andre G Uitterlinden, Ingileif Jonsdottir, Kari Stefansson, P Eline Slagboom, Eleftheria Zeggini, Ingrid Meulenbelt, John PA Ioannidis, Tim D Spector, Joyce B J van Meurs, Ana M Valdes
• Extended report: Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis (16 August, 2013)

  Denis Poddubnyy, Kristina Conrad, Hildrun Haibel, Uta Syrbe, Heiner Appel, Jürgen Braun, Martin Rudwaleit, Joachim Sieper
• The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis

  (26 August, 2013)

  Janet E Pope, Boulos Haraoui, J Carter Thorne, Andrew Vieira, Melanie Poulin-Costello, Edward C Keystone
• Extended report: Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial (3 September, 2013)

  Michael E Weinblatt, Rene Westhovens, Alan M Mendelsohn, Lilianne Kim, Kim Hung Lo, Shihong Sheng, Lenore Noonan, Jiandong Lu, Zhenhua Xu, Jocelyn Leu, Daniel Baker, Clifton O Bingham
• Extended report: The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry (21 August, 2013)

  H J Lachmann, R Papa, K Gerhold, L Obici, I Touitou, L Cantarini, J Frenkel, J Anton, I Kone-Paut, M Cattalini, B Bader-Meunier, A Insalaco, V Hentgen, R Merino, C Modesto, N Toplak, R Berendes, S Ozen, R Cimaz, A Jansson, P A Brogan, P N Hawkins, N Ruperto, A Martini, P Woo, M Gattorno
• Extended report: Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes (11 September, 2013)

  Maryam Piram, Isabelle Koné-Paut, Helen J Lachmann, Joost Frenkel, Seza Ozen, Jasmin Kuemmerle-Deschner, Silvia Stojanov, Anna Simon, Martina Finetti, Maria Pia Sormani, Alberto Martini, Marco Gattorno, Nicolino Ruperto
• Concise report: Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase (27 June, 2014)

  Michael H Schiff, Johannes von Kempis, Ronald Goldblum, John R Tesser, Ruediger B Mueller
• Concise report: Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up (12 August, 2014)

  Erik H Vogelzang, Eva L Kneepkens, Michael T Nurmohamed, Arno W R van Kuijk, Theo Rispens, Gertjan Wolbink, Charlotte L M Krieckaert